Immunity-and-Matrix-Regulatory Cells Derived from Human Embryonic Stem Cells Safely and Effectively Treat Mouse Lung Injury and Fibrosis

Jun Wu; Dingyun Song; Zhongwen Li; Baojie Guo; Yani Xiao; Wenjing Liu; Lingmin Liang; Chunjing Feng; Tingting Gao; Zai Wang; Jianyan Wen; Shengnan Yang; Peipei Liu; Lei Wang; Yukai Wang; Liang Peng; Guihai Feng; Shiqiang Huang; Glyn Nigel Stacey; Wei Li; Yan Huo; Ronghua Jin; Qi Zhou; Liu Wang; Baoyang Hu; Huaping Dai; Jie Hao

The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.15.042119 doi: bioRxiv preprint Tumorigenicity has long been an obstacle to the clinical application of cells derived from hESCs, due to 454 the contamination of residual hESCs that could form teratomas. Our single cell RNA sequencing showed 455 that no residual OCT4/SOX2/NANOG/TERT/DPPA5 + hESCs remained amongst the IMRCs, and that 456 all pluripotency gene expression had been extinguished (Fig. 5A) . To ensure their short-term and long-457 term safety, a series of biosafety-related experiments were performed according to the "Guidelines for Table S1 ). These biosafety-related 461 experiments included testing for bacteria, fungi, mycoplasma, virus (by in vivo and in vitro methods), 462 pluripotent cell residuals, tumorigenicity and biopreparation safety (endotoxin and bovine serum albumin 463 residuals). According to these tests, the safety of the IMRCs has been verified as required by the National 464